About Ziprasidone Hydrochloride API
Therapeutic Category中枢神経系 (CNS)
API Technology
Synthetic
Dose Form
Oral Solid/Capsules, Suspension
Dr Reddy's Development Status
Available (Commercial)
Available Regulatory Filing
USDMF, CEP Submitted, Brazil DMF, EUDMF
Mechanism of Action
The mechanism of action of ziprasidone, as with other drugs having efficacy in schizophrenia, is unknown. However, it has been proposed that this drug’s efficacy in schizophrenia is mediated through a combination of dopamine type 2 (D2) and serotonin type 2 (5HT2) antagonism. As with other drugs having efficacy in bipolar disorder, the mechanism of action of ziprasidone in bipolar disorder is unknown.
Indication
GEODON is an atypical antipsychotic. In choosing among treatments, prescribers should be aware of the capacity of GEODON to prolong the QT interval and may consider the use of other drugs first GEODON is indicated as an oral formulation for the:
Treatment of schizophrenia.
- Adults: Efficacy was established in four 4-6 week trials and one maintenance trial in adult patients with schizophrenia. (14.1) Acute treatment as monotherapy of manic or mixed episodes associated with bipolar I disorder.
- Adults: Efficacy was established in two 3-week trials in adult patients with manic or mixed episodes. Maintenance treatment of bipolar I disorder as an adjunct to lithium or valproate.
- Adults: Efficacy was established in one maintenance trial in adult patients. GEODON as an intramuscular injection is indicated for the: Acute treatment of agitation in schizophrenic patients.
- Adults: Efficacy was established in two short-term trials in agitated patients with schizophrenia.
Dr. Reddy's Expertise
Headquartered in Hyderabad, India, Dr. Reddy's Laboratories is one of the leading Active Pharmaceutical Ingredients (API) manufacturers and suppliers globally for Ziprasidone Hydrochloride API. Dr. Reddy's API business is a preferred partner to pharma companies across the US, Europe, Brazil, Latin America, Japan, China, Korea, Middle East and other emerging markets.
Dr. Reddy's API business thrives on the deep technical strengths established over the last 30+ years in the development and manufacture of complex APIs such as steroids, peptides, complex long chain molecules and highly potent APIs (HPAPIs / oncology drugs). This expertise is complemented by our prowess in intellectual property and regulatory affairs which helps us consistently meet and exceed regulatory standards. Dr. Reddy's Ziprasidone Hydrochloride API is the outcome of the extensive expertise in R&D, IP, and Regulatory.
A key component in helping our customers be first to market is a responsive supply chain. We achieve this by making sure that all our facilities are operating efficiently and to the latest standards of quality, safety, and productivity. A strong interconnect between business and factories allows for a quick reaction to dynamic market changes, so that we can avert shortages and meet sudden surges in demand.
Request for Quotation
Get in touch with us by filling out the form below. Our team will reach out to you shortly!
FAQs
It belongs to the class of Anti-psychotics
It is a CNS drug used to treat Schizophrenia
The safety dose for Ziprasidone is 20, 40, 60 & 80MG BASE and 10MG BASE/ML
We offer Anhydrous form
Meet with our product experts in one-on-one virtual sessions at https://api.drreddys.com/meet-api-experts or Write to us at [email protected].
免責事項
このウェブサイト上のいかなる情報も、製品またはサービスへの言及を含め、販売の申し出を構成するものではなく、販売の申し出を表すものと解釈されるものでもありません。有効な特許により保護されている製品は、商用目的で提供または提供されるものではありません。ただし、特定のケースでは、Dr. Reddy の独自の裁量により、現地の法的要件に従って、そのような製品の研究用数量が、規制免除が存在する場所に、インド特許法第 107A 条 (Bolar 免除) に基づく規制提出の目的で提供される場合があります。購入者は、それぞれの市場における特許シナリオを含む製品またはサービスについて独自の評価を行う必要があり、すべての特許関連法的責任を負うことになります。Dr. Reddy は、商品性、特定目的への適合性、および非侵害の保証を含むがこれらに限定されない、明示または黙示を問わずすべての保証を否認します。